Health-related quality-of-life analyses from a multicenter, randomized, double-blind phase 2 study of patients with differentiated thyroid cancer treated with lenvatinib 18 or 24 mg/day

By sjmartinez • March 3, 2023

Taylor MH, Leboulleux S, Panaseykin Y, Konda B, de La Fouchardiere C, Hughes BGM, Gianoukakis AG, Park YJ, Romanov I, Krzyzanowska MK, Garbinsky D, Sherif B, Pan JJ, Binder TA, Sauter N, Xie R, Brose MS. Health-related quality-of-life analyses from a multicenter, randomized, double-blind phase 2 study of patients with differentiated thyroid cancer treated with lenvatinib 18 or 24 mg/day. Cancer Med. 2023 Feb;12(4):4332-4342. doi: 10.1002/cam4.5308. Epub 2022 Dec 4. PMID: 36464853; PMCID: PMC9972135.

Tags: dose intensity, Endocrinology, Harbor UCLA, HRQoL, kinase inhibitor, lenvatinib, Quality of Life, radioiodine-refractory differentiated thyroid cancer

Stabilizing and strengthening the U.S. physician-scientist faculty workforce in academic medicine: a proposed institutional framework

Williams CS, Allen M, Cooper Byas P, Hawley JB, Muglia LJ, Abel ED, Bastarache JA, Calfee CS, Carethers JM, Cornfield DN, Eickelberg O, Gallagher EJ,[...]

The effectiveness of care coordination on medication adherence among high-need, high-cost commercially insured beneficiaries: A randomized controlled trial

Saju R, Harwood JM, Tseng CH, Moin T, Mangione C, Duru OK, Takada S, Onufrak S. The effectiveness of care coordination on medication adherence among[...]

Systems Genetics Reveals ITIH5 as a Key Mediator of Adipocyte-Endothelial Crosstalk

Zhou M, Velez LM, Kwan D, Moses L, Johnson CD, Nguyen CM, Mott L, Gamie F, Fouladi M, Bae H, Verlande A, Arneson D, Petrus[...]